Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 367268, 9 pages
http://dx.doi.org/10.1155/2014/367268
Research Article

The Structural Modeling of the Interaction between Levofloxacin and the Mycobacterium tuberculosis Gyrase Catalytic Site Sheds Light on the Mechanisms of Fluoroquinolones Resistant Tuberculosis in Colombian Clinical Isolates

1Corporación Para Investigaciones Biológicas—(CIB), Bacteriology and Mycobacteria Unit, Carrera 72a N 78B-141, Medellín, Colombia
2Universidad Pontificia Bolivariana—(UPB), Calle 78b No. 72a-109, Medellín, Colombia
3Escuela de Ingeniería de Antioquia, Km 2 + 200 Vía al Aeropuerto José María Córdova, Envigado, Colombia
4Grupo Interdisciplinario de Estudios Moleculares—(GIEM), Universidad de Antioquia, Calle 67 No. 108-53, Medellín, Colombia
5Equal Opportunity Life Sciences, 1132 Parrish Drive, Rockville, MD 20851, USA

Received 11 October 2013; Accepted 12 February 2014; Published 28 April 2014

Academic Editor: Jakko van Ingen

Copyright © 2014 N. Alvarez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, Global Tuberculosis Report, World Health Organization, Geneva, Switzerland, 2012.
  2. P. Nunn, “The global control of tuberculosis: what are the prospects?” Scandinavian Journal of Infectious Diseases, vol. 33, no. 5, pp. 329–332, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. WHO, Framework for Effective Tuberculosis Control, World Health Organization, Geneva, Switzerland, 1994.
  4. A. Kochi, “Tuberculosis control- Is dots the health breakthrough of the 1990s?” World Health Forum, vol. 18, no. 3-4, pp. 225–232, 1997. View at Google Scholar · View at Scopus
  5. S. Keshavjee and P. E. Farmer, “Tuberculosis, drug resistance and the history of modern medicine,” The New England Journal of Medicine, vol. 367, pp. 931–936, 2012. View at Google Scholar
  6. M. E. Villarino, L. J. Geiter, and P. M. Simone, “The multidrug-resistant tuberculosis challenge to public health efforts to control tuberculosis,” Public Health Reports, vol. 107, no. 6, pp. 616–625, 1992. View at Google Scholar · View at Scopus
  7. K. Mdluli and Z. Ma, “Mycobacterium tuberculosis DNA gyrase as a target for drug discovery,” Infectious Disorders—Drug Targets, vol. 7, no. 2, pp. 1–10, 2007. View at Google Scholar
  8. S. S. Hegde, M. W. Vetting, S. L. Roderick et al., “A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA,” Science, vol. 308, no. 5727, pp. 1480–1483, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. R. O. 'Donnell and J. J. Saukkonen, “Antimycobacterial agents,” in Harrison's Principles of Internal Medicine, D. L. Longo, A. S. Fauci, D. L. Kasper, S. L. Hauser, J. L. Jameson, and J. Loscalzo, Eds., McGraw-Hill, New York, NY, USA, 2012, http://www.accessmedicine.com/content.aspx?aID=9122997.
  10. Centers for Disease Control and Prevention (CDC), “Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000–2004,” Morbidity and Mortality Weekly Report, vol. 55, no. 11, pp. 301–305, 2006. View at Google Scholar
  11. C. Pierre-Audigier and B. Gicquel, “The contribution of molecular biology in diagnosing tuberculosis and detecting antibiotic resistance,” 2012, http://www.moleculartb.org/gb/pdf/doc/Revue.pdf.
  12. Y. Y. Huang, J. Y. Deng, J. Gu et al., “The key DNA-binding residues in the C-terminal domain of Mycobacterium tuberculosis DNA gyrase A subunit (GyrA),” Nucleic Acids Research, vol. 34, no. 19, pp. 5650–5659, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. E. F. F. da Cunha, E. F. Barbosa, A. A. Oliveira, and T. C. Ramalho, “Molecular modeling of Mycobacterium tuberculosis DNA gyrase and its molecular docking study with gatifloxacin inhibitors,” Journal of Biomolecular Structure and Dynamics, vol. 27, no. 5, pp. 1–6, 2010. View at Google Scholar · View at Scopus
  14. N. Minovski, M. Vračko, and T. Šolmajer, “Quantitative structure-activity relationship study of antitubercular fluoroquinolones,” Molecular Diversity, vol. 15, no. 2, pp. 417–426, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. J. I. Sekiguchi, T. Miyoshi-Akiyama, E. Augustynowicz-Kopeć et al., “Detection of multidrug resistance in Mycobacterium tuberculosis,” Journal of Clinical Microbiology, vol. 45, no. 1, pp. 179–192, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Kim, C. Nakajima, Y. U. Kim, K. Yokoyama, and Y. Suzuki, “Influence of lineage-specific amino acid dimorphisms in GyrA on Mycobacterium tuberculosis resistance to fluoroquinolones,” Japanese Journal of Infectious Diseases, vol. 65, no. 1, pp. 72–74, 2012. View at Google Scholar · View at Scopus
  17. A. Pantel, S. Petrella, N. Veziris et al., “Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 4, pp. 1990–1996, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. G. G. Zhanel, S. Fontaine, H. Adam et al., “A review of new fluoroquinolones: focus on their use in respiratory tract infections,” Treatments in Respiratory Medicine, vol. 5, no. 6, pp. 437–465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. D. N. Fish and A. T. Chow, “The clinical pharmacokinetics of levofloxacin,” Clinical Pharmacokinetics, vol. 32, no. 2, pp. 101–119, 1997. View at Google Scholar · View at Scopus
  20. M. C. Garzón, D. Y. Angée, C. Llerena et al., “Vigilancia de la resistencia del Mycobacterium tuberculosis a los fármacos antituberculosos, Colombia 2004–2005,” Biomédica, vol. 28, pp. 319–326, 2008. View at Google Scholar
  21. “Departamento Administrativo Nacional de Estadística (DANE). Encuesta Nacional de Ingresos y Gastos 2006–2007. 2012,” http://www.dane.gov.co.
  22. Dirección Seccional de Salud y Protección Social de Antioquia. Boletín información para la acción (BIA), 2012.
  23. “Antioquia Gobernment,” 2012, http://www.antioquia.gov.co.
  24. J. A. Robledo, G. I. Mejía, N. Morcillo et al., “Evaluation of a rapid culture method for tuberculosis diagnosis: a Latin American multi-center study,” International Journal of Tuberculosis and Lung Disease, vol. 10, no. 6, pp. 613–619, 2006. View at Google Scholar · View at Scopus
  25. CLSI, Susceptibility testing of Mycobacteria, Nocardiae and other aerobic Actinomycetes, Approved Standard-Second edition. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 2011.
  26. D. van Soolingen, P. E. W. de Haas, P. W. M. Hermans, and J. D. A. van Embden, “DNA fingerprinting of Mycobacterium tuberculosis,” Methods in Enzymology, vol. 235, pp. 196–205, 1994. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Springer, K. Lucke, R. Calligaris-Maibach, C. Ritter, and E. C. Böttger, “Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation,” Journal of Clinical Microbiology, vol. 47, no. 6, pp. 1773–1780, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. J. S. Dewar, E. G. Zoebisch, E. F. Healy, and J. J. P. Stewart, “AM1: a new general purpose quantum mechanical molecular model,” Journal of the American Chemical Society, vol. 107, no. 13, pp. 3902–3909, 1985. View at Google Scholar · View at Scopus
  29. N. R. Gandhi, P. Nunn, K. Dheda et al., “Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis,” The Lancet, vol. 375, no. 9728, pp. 1830–1843, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Sandgren, M. Strong, P. Muthukrishnan, B. K. Weiner, G. M. Church, and M. B. Murray, “Tuberculosis drug resistance mutation database,” PLoS Medicine, vol. 6, no. 2, Article ID e1000002, pp. 0132–0136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Dalhoff, “Global fluoroquinolone resistance epidemiology and implictions for clinical use,” Interdisciplinary Perspectives on Infectious Diseases, pp. 1–37, 2012. View at Google Scholar
  32. N. Bhatti, N. Chronos, J. P. White, and E. Larson, “A case of resistant tuberculosis,” Tubercle, vol. 71, no. 2, pp. 141–143, 1990. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Y. Chiang and H. S. Schaaf, “Management of drug-resistant tuberculosis,” International Journal of Tuberculosis and Lung Disease, vol. 14, no. 6, pp. 672–682, 2010. View at Google Scholar · View at Scopus
  34. T. Dalton, P. Cegielski, S. Akksilp et al., “Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study,” The Lancet, vol. 380, pp. 1406–1417, 2012. View at Google Scholar
  35. E. Nosova, A. Bukatina, Y. Isaeva et al., “Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacteriumtuberculosis to levofloxacin, moxifloxacin and gatifloxacin,” Journal of Medical Microbiology, vol. 62, pp. 108–113, 2012. View at Google Scholar
  36. V. Ritacco, B. Lopéz, M. Ambroggi et al., “HIV infection and geographically bound transmission of drug-resistant tuberculosis, Argentina,” Emerging Infectious Diseases, vol. 18, no. 11, pp. 1802–1810, 2012. View at Google Scholar
  37. H. E. Takiff, L. Salazar, C. Guerrero et al., “Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations,” Antimicrobial Agents and Chemotherapy, vol. 38, no. 4, pp. 773–780, 1994. View at Google Scholar · View at Scopus
  38. A. von Groll, A. Martin, P. Jureen et al., “Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 10, pp. 4498–4500, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Zhang and A. Telenti, “Genetics of drug resistance in Mycobacterium tuberculosis,” in Molecular Genetics of Mycobacteria, G. F. Hatfull and W. R. Jacobs Jr., Eds., pp. 235–254, ASM Press, Washington, DC, USA, 2000. View at Google Scholar
  40. Y. Suzuki, C. Nakajima, A. Tamaru, H. Kim, T. Matsuba, and H. Saito, “Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance,” International Journal of Antimicrobial Agents, vol. 39, no. 5, pp. 435–439, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Shi, J. Zhang, C. Li, Y. Kazumi, and I. Sugawara, “Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing,” Journal of Clinical Microbiology, vol. 44, no. 12, pp. 4566–4568, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Pitaksajjakul, W. Wongwit, W. Punprasit, B. Eampokalap, S. Peacock, and P. Ramasoota, “Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand,” The Southeast Asian Journal of Tropical Medicine and Public Health, vol. 36, pp. 228–237, 2005. View at Google Scholar · View at Scopus
  43. M. R. Pasca, P. Guglierame, F. Arcesi, M. Bellinzoni, E. de Rossi, and G. Riccardi, “Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 8, pp. 3175–3178, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. K. M. Kam, C. W. Yip, T. L. Cheung, H. S. Tang, O. C. Leung, and M. Y. Chan, “Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility,” Microbial Drug Resistance, vol. 12, no. 1, pp. 7–11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. D. L. Ross and C. M. Riley, “Aqueous solubilities of some variously substituted quinolone antimicrobials,” International Journal of Pharmaceutics, vol. 63, no. 3, pp. 237–250, 1990. View at Publisher · View at Google Scholar · View at Scopus
  46. F. M. Barnard and A. Maxwell, “Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser83 and Asp87,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 7, pp. 1994–2000, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. E. M. Streicher, I. Bergval, K. Dheda et al., “Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 5, pp. 2420–2427, 2012. View at Publisher · View at Google Scholar · View at Scopus